Lyubov Slashcheva, Rick Rader, MD, and Stephen B. Sulkes, MD
Designation of people with intellectual and developmental disabilities as a medically underserved population would not solve problems of access to care.
AMA J Ethics. 2016;18(4):422-429. doi:
10.1001/journalofethics.2016.18.4.pfor1-1604.
Clinicians with obligations to patients and to organizations often assess patients in law enforcement for both therapeutic and nontherapeutic purposes.
AMA J Ethics. 2022;24(2):E111-119. doi:
10.1001/amajethics.2022.111.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Health care reform expanded health insurance to millions, but current community benefit policies must be used by organizations hoping to address social determinants.
AMA J Ethics. 2019;21(3):E248-258. doi:
10.1001/amajethics.2019.248.
Where people live and work influences how long and how well they live. Supporting community investments can diminish risk, improve outcomes, and reduce costs.
AMA J Ethics. 2019;21(3):E262-268. doi:
10.1001/amajethics.2019.262.
Workplace wellness programs contribute to the wellness movement by enlisting nontraditional health partners and influencing social determinants of health.
AMA J Ethics. 2016;18(4):393-398. doi:
10.1001/journalofethics.2016.18.4.nlit1-1604.